Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Ryman-Tubb T, Lothion-Roy JH, Metzler VM, Harris AE, Robinson BD, Rizvanov AA, et al. Comparative pathology of dog and human prostate cancer. Vet Med Sci. 2021.

Liu X, Su T, Hsu Y-, Yu H, Yang HS, Jiang L, et al. Rapid identification and discrimination of methicillin-resistant Staphylococcus aureus strains via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 2021;35(2):e8972.

Olson LC, Lelli GJ, Patel SS, Magro CM. Conjunctival Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) in a Young Adult Male With Persistent Ptosis. J Clin Rheumatol. 2021;27(2):e53-e58.

Hwang I, Uchida H, Dai Z, Li F, Sanchez T, Locasale JW, et al. Cellular stress signaling activates type-I IFN response through FOXO3-regulated lamin posttranslational modification. Nat Commun. 2021;12(1):640.

Trzebucki AM, Westblade LF, Loo A, Mazur S, Jenkins SG, Calfee DP, et al. Real-world implementation and impact of a rapid carbapenemase detection test in an area endemic for carbapenem-resistant Enterobacterales. Infect Control Hosp Epidemiol. 2021:1-4.

Baquero J, Tang X-, Scognamiglio T, Gudas LJ. EZH2 Knockout in Oral Cavity Basal Epithelia Causes More Invasive Squamous Cell Carcinomas. Carcinogenesis. 2021.

Vicier C, Ravi P, Kwak L, Werner L, Huang Y, Evan C, et al. Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer. Prostate. 2021;81(1):50-57.

Cazer CL, Westblade LF, Simon MS, Magleby R, Castanheira M, Booth JG, et al. Analysis of Multidrug Resistance in Staphylococcus aureus with a Machine Learning-Generated Antibiogram. Antimicrob Agents Chemother. 2021;65(4).

Yin Y, Zhu L, Li Q, Zhou P, Ma L. Cullin4 E3 Ubiquitin Ligases Regulate Male Gonocyte Migration, Proliferation and Blood-Testis Barrier Homeostasis. Cells. 2021;10(10).

Sun M, Schaap A, Robinson BD, Nanus DM, Tagawa ST. A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. Am J Clin Exp Urol. 2021;9(5):390-396.